ベバシズマブ投与が右下腿皮膚潰瘍の増悪に影響を与えた1例

A Skin Ulcer on the Lower Right Leg Caused by Bevacizumab Treatment

はじめに

　ベバシズマブ（以下，Bmab）は，抗VEGFヒト化モノクローナル抗体で血管新生を遮断する抗悪性腫瘍薬であり，手術不能または再発乳癌に適応がある。Bmabの特徴的な有害事象に高血圧症，出血，蛋白尿，血栓塞栓症，創傷治癒遅延などがある 1）。今回われわれはBmabの投与中に増悪した右下腿難治性潰瘍の治療経験について若干の文献的考察を交えて報告する。

　Bevacizumab (Bmab) is a monoclonal antibody that exerts its antitumor activity by inhibiting vascular endothelial growth factor (VEGF). Consequently, Bmab suppresses endothelial cell proliferation, vascular permeability, and angiogenesis. The characteristic potential adverse events of Bmab treatment include hypertension, bleeding, proteinuria, thromboembolism, and delayed wound healing. We encountered a case in which an intractable ulcer developed in the patientʼs lower right leg and is thought to have been caused by the administration of Bmab. We provide the case details and a consideration of the relevant literature.